- Reaction score
- 97
My thought about dNovo bio that is troubling is their size. Only 3 people! Yikes! Compare that to Stemson Therapeutics having around 2 dozen people with specialized areas of knowledge and a lot more money. What's the likelihood of dNovo bio making a leap in progress having so few individuals working there? They need to expand their size. The good thing is they got money granted to them too, around 2.2 million or so but their minimal funding will hold them back too. They need to attract more investment somehow to expand. The need for funding is crucial just to do pre-clinical and clinical trials. Then there's salaries, machinery needed, outside help, utilities, etc. Government wastes so much of our money on things that make us miserable (likely causing us to lose our hair) but to do something with our money that can benefit people's quality of life somehow that is not the case. If any group had unlimited money I'm wondering how much faster progress would come? For example, does Stemson Therapeutics have enough money right now to do everything they need or are certain things lacking due to lack of funds?